ABSTRACT
Nucleic acid sequencing technologies have advanced significantly in recent years, allowing the development of liquid biopsies as new means to detect cancer biomarkers and cancer heterogenicity. Most of the assays available clinically focus on cell free DNA, however, cell free RNA (cfRNA) is also present and has the potential to complement and improve cancer detection especially in cancers like lung cancer, which are usually only diagnosed at late stages and therefore have poor long-term survival outcomes. Remnant EDTA plasma was collected from lung cancer patients and non-cancer individuals at the University of Maryland Medical Center. RNA was extracted and processed for next generation sequencing with a tagmentation-based library preparation approach. cfRNA was successfully extracted and sequenced from 52 EDTA-treated plasma samples with volumes as low as 1.5 mL. This quantity was sufficient to prepare libraries with the length of libraries averaging from 264bp to 381bp and resulted in over 2.2 to 3.6 million total sequence reads respectively. Sequential dilution of cfRNA samples from healthy individuals indicated that the starting cfRNA concentration influenced the detection of differentially expressed genes. This proof-of-concept study provides a framework for screening cfRNA for identifying biomarkers for early detection of lung cancer (and other cancers), using minimal amounts of samples (1.5 ml) from standard EDTA 3-mL collection tubes routinely used for patient care. Further studies in large populations are required to establish limit of detection and other parameters including precision, accuracy, sensitivity, and specificity, to standardize this method.
Competing Interest Statement
Amol Carl Shetty and Kristin Mullins disclose discounted reagents from Illumina, Inc. Sanford A Stass discloses grants from NIH/NCI, and reduction in cost of reagents from Illumina. Chamindi Seneviratne discloses discounted reagents from Illumina, Inc, and grants from NIH/NIAAA (K23AA020899) for the collection of control samples identified as "Set 2", and 5R01AA026291. Feng Jiang discloses grants FDA-5U01FD005946-06 and NCI-UH2CA229132.
Funding Statement
NCI-U24CA11509-01 (SS), FDA-5U01FD005946-06(FJ), and NCI-UH2CA229132 (FJ), and in part by NIAAA grant K23AA020899 (CS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Maryland gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
